These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 34959132)

  • 21. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.
    Feng X; Yin J; Zhang J; Hu Y; Ouyang Y; Qiao S; Zhao H; Zhang T; Li X; Zhang L; Zhang J; Jin R; Feng Y; Su B
    Front Immunol; 2021; 12():614436. PubMed ID: 33790892
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Spin Columns for Human Plasma Depletion to Facilitate MS-Based Proteomics Analysis of Plasma.
    Cao X; Sandberg A; Araújo JE; Cvetkovski F; Berglund E; Eriksson LE; Pernemalm M
    J Proteome Res; 2021 Sep; 20(9):4610-4620. PubMed ID: 34320313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular and serological characterization of SARS-CoV-2 infection among COVID-19 patients.
    Li L; Liang Y; Hu F; Yan H; Li Y; Xie Z; Huang L; Zhao J; Wan Z; Wang H; Shui J; Cai W; Tang S
    Virology; 2020 Dec; 551():26-35. PubMed ID: 33011520
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sinonasal manifestations and dynamic profile of RT-PCR results for SARS-CoV-2 in COVID-19 patients.
    Jia X; Shao S; Ren H; Xu Y; Zhao J; Zhao Y; Wang Y; Bao S; Yan J; Wang X; Zhang L
    Ann Palliat Med; 2021 Apr; 10(4):4174-4183. PubMed ID: 33832289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathological features of COVID-19-associated lung injury: a preliminary proteomics report based on clinical samples.
    Leng L; Cao R; Ma J; Mou D; Zhu Y; Li W; Lv L; Gao D; Zhang S; Gong F; Zhao L; Qiu B; Xiang H; Hu Z; Feng Y; Dai Y; Zhao J; Wu Z; Li H; Zhong W
    Signal Transduct Target Ther; 2020 Oct; 5(1):240. PubMed ID: 33060566
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Looking for pathways related to COVID-19: confirmation of pathogenic mechanisms by SARS-CoV-2-host interactome.
    Messina F; Giombini E; Montaldo C; Sharma AA; Zoccoli A; Sekaly RP; Locatelli F; Zumla A; Maeurer M; Capobianchi MR; Lauria FN; Ippolito G
    Cell Death Dis; 2021 Aug; 12(8):788. PubMed ID: 34385425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamic and features of SARS-CoV-2 infection in Gabon.
    Mveang Nzoghe A; Padzys GS; Maloupazoa Siawaya AC; Kandet Yattara M; Leboueny M; Avome Houechenou RM; Bongho EC; Mba-Mezeme C; Mvoundza Ndjindji O; Biteghe-Bi-Essone JC; Boulende A; Essone PN; Ndong Sima CAA; Minkobame U; Zang Eyi C; Ndeboko B; Voloc A; Meye JF; Ategbo S; Djoba Siawaya JF
    Sci Rep; 2021 May; 11(1):9672. PubMed ID: 33958601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunoreactive peptide maps of SARS-CoV-2.
    Mishra N; Huang X; Joshi S; Guo C; Ng J; Thakkar R; Wu Y; Dong X; Li Q; Pinapati RS; Sullivan E; Caciula A; Tokarz R; Briese T; Lu J; Lipkin WI
    Commun Biol; 2021 Feb; 4(1):225. PubMed ID: 33580175
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ocular Involvement of SARS-CoV-2 in a Polish Cohort of COVID-19-Positive Patients.
    Dolar-Szczasny J; Toro MD; Dworzańska A; Wójtowicz T; Korona-Glowniak I; Sawicki R; Boguszewska A; Polz-Dacewicz M; Tomasiewicz K; Załuska W; Rejdak R; Bagnoli P; Rusciano D
    Int J Environ Res Public Health; 2021 Mar; 18(6):. PubMed ID: 33809199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders.
    Marklund E; Leach S; Axelsson H; Nyström K; Norder H; Bemark M; Angeletti D; Lundgren A; Nilsson S; Andersson LM; Yilmaz A; Lindh M; Liljeqvist JÅ; Gisslén M
    PLoS One; 2020; 15(10):e0241104. PubMed ID: 33085715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protocol for global proteome, virome, and metaproteome profiling of respiratory specimen (VTM) in COVID-19 patient by LC-MS/MS-based analysis.
    Tripathi G; Sharma N; Bindal V; Yadav M; Mathew B; Sharma S; Gupta E; Singh Maras J; Sarin SK
    STAR Protoc; 2022 Mar; 3(1):101045. PubMed ID: 34870243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum Protein Profiling Reveals a Specific Upregulation of the Immunomodulatory Protein Progranulin in Coronavirus Disease 2019.
    Rieder M; Wirth L; Pollmeier L; Jeserich M; Goller I; Baldus N; Schmid B; Busch HJ; Hofmann M; Thimme R; Rieg S; Kern W; Bode C; Duerschmied D; Lother A
    J Infect Dis; 2021 Mar; 223(5):775-784. PubMed ID: 33249471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. COVID-19 Coronavirus Vaccine Design Using Reverse Vaccinology and Machine Learning.
    Ong E; Wong MU; Huffman A; He Y
    Front Immunol; 2020; 11():1581. PubMed ID: 32719684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mass spectrometry-based proteomic platforms for better understanding of SARS-CoV-2 induced pathogenesis and potential diagnostic approaches.
    Ahsan N; Rao RSP; Wilson RS; Punyamurtula U; Salvato F; Petersen M; Ahmed MK; Abid MR; Verburgt JC; Kihara D; Yang Z; Fornelli L; Foster SB; Ramratnam B
    Proteomics; 2021 May; 21(10):e2000279. PubMed ID: 33860983
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients.
    Lafon E; Diem G; Witting C; Zaderer V; Bellmann-Weiler RM; Reindl M; Bauer A; Griesmacher A; Fux V; Hoermann G; Miller C; Zabernigg A; Wöll E; Wilflingseder D; Lass-Flörl C; Posch W
    Front Immunol; 2021; 12():684014. PubMed ID: 34194438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring novel and potent cell penetrating peptides in the proteome of SARS-COV-2 using bioinformatics approaches.
    Kardani K; Bolhassani A
    PLoS One; 2021; 16(2):e0247396. PubMed ID: 33606823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SARS-CoV-2 N-antigenemia in critically ill adult COVID-19 patients: Frequency and association with inflammatory and tissue-damage biomarkers.
    Olea B; Albert E; Torres I; Gozalbo-Rovira R; Carbonell N; Ferreres J; Poujois S; Costa R; Colomina J; Rodríguez-Díaz J; Blasco ML; Navarro D
    J Med Virol; 2022 Jan; 94(1):222-228. PubMed ID: 34449894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low prevalence of SARS-CoV-2 in plasma of COVID-19 patients presenting to the emergency department.
    Nijhuis RHT; Russcher A; de Jong GJ; Jong E; Herder GJM; Remijn JA; Verweij SP
    J Clin Virol; 2020 Dec; 133():104655. PubMed ID: 33069846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms: A Case Series.
    Edén A; Kanberg N; Gostner J; Fuchs D; Hagberg L; Andersson LM; Lindh M; Price RW; Zetterberg H; Gisslén M
    Neurology; 2021 Jan; 96(2):e294-e300. PubMed ID: 33004602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19.
    Underwood AP; Sølund C; Fernandez-Antunez C; Villadsen SL; Winckelmann AA; Bollerup S; Mikkelsen LS; Sørensen AL; Feng S; Fahnøe U; Lassauniere R; Fomsgaard A; Ramirez S; Weis N; Bukh J
    EBioMedicine; 2021 Sep; 71():103519. PubMed ID: 34419923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.